Nothing 20 2

SEBI Likely to Announce Settlement Scheme for Commodity Brokers in NSEL Case

The Securities and Exchange Board of India (SEBI) is expected to introduce a settlement scheme for commodity brokers involved in the long-standing National Spot Exchange Limited (NSEL) case. The proposal is likely to be tabled at SEBI’s June 2025 board meeting, marking a significant step toward resolving regulatory overhangs. Key Developments & Eligibility Criteria Industry…

Read More
Nothing 19 2

Neogen Chemicals Targets ₹850 Crore Revenue in FY26 Amid Expansion Plans

Neogen Chemicals Ltd., a leading specialty chemicals manufacturer, has set an ambitious revenue target of ₹775–₹850 crore for FY26, despite facing operational setbacks earlier this year. Growth Drivers & Expansion Strategy Financial Outlook & Market Position Neogen Chemicals anticipates 10% revenue growth over FY25, with a long-term target of ₹1,000–₹1,100 crore in FY27. The company…

Read More
Nothing 18 2

SEBI Chief Tuhin Kanta Pandey Vows Transparency Amid Disclosure Concerns

Securities and Exchange Board of India (SEBI) Chairman Tuhin Kanta Pandey has pledged to tackle disclosure gaps head-on, acknowledging that virtually no public disclosure existed for SEBI’s leadership before his tenure. Key Concerns & Regulatory Actions Market Reaction & Governance Reforms Future Outlook & Policy Changes Pandey emphasized that transparency and accountability will be central…

Read More
Nothing 15 3

Religare Enterprises Q4 Results: Net Profit Falls 16% to ₹151 Crore, Revenue Climbs 9%

Religare Enterprises Ltd. has reported a 16.4% year-on-year (YoY) decline in net profit, totaling ₹151.3 crore for Q4 FY25. Despite the profit dip, the company’s revenue from operations grew 9.3% YoY, reaching ₹2,028 crore. Key Financial Highlights Burman Group’s Takeover & Strategic Direction Earlier this year, the Burman family acquired control of Religare Enterprises, securing…

Read More
Nothing 14 3

Zydus Lifesciences Targets FY26 Expansion Amid Slower US Growth Post-Revlimid Peak

Zydus Lifesciences Ltd. has outlined its FY26 expansion strategy, aiming for double-digit revenue growth, despite slower momentum in the US market following the peak sales of its blockbuster generic drug Revlimid. Key Financial Highlights & Growth Strategy Pipeline & Expansion Plans Zydus is banking on 14–15 critical launches in FY27, including complex generics with semi-exclusive…

Read More
Nothing 11 3

Colgate-Palmolive India Q4 Results: Profit Falls Over 6% But Meets Estimates

Colgate-Palmolive (India) Ltd. has reported a 6.5% year-on-year decline in net profit, totaling ₹355 crore for Q4 FY25. Despite the dip, the results aligned with analyst expectations, reflecting stable operational performance amid market challenges. Key Financial Highlights Market Reaction & Investor Sentiment Despite the profit decline, Colgate-Palmolive’s stock closed 1.16% higher at ₹2,660 on the…

Read More